Julia Stephanus
Julia has been a visionary entrepreneur and strategic brand builder in the veterinary industry for 30+ years. Her achievements include building and scaling two successful start-up veterinary pharmaceutical businesses and launching 28 veterinary products. She was Founder and CEO of Summit VetPharm, which exited to Ceva Animal Health in 2010. As Chief Commercial Officer of Aratana Therapeutics (PETX), she was instrumental in the IPO and the buildout of a fully integrated commercial organization. Julia led the co-promotion and the licensing of Aratana’s lead osteoarthritis product, Galliprant®, to Elanco. Aratana exited to Elanco in 2019.
Julia is Founder and President of Avviare, LLC, providing consulting services to start-ups and established players in veterinary biopharmaceuticals. In addition to the start-up experience, Julia’s career includes senior-level positions at Ceva, Forest Laboratories (Allergan) and Pfizer Animal Health (Zoetis) and their legacy companies.
Julia presently serves on the Boards of PBI Gordon, ReduxBio, and Jenga Biosciences. Julia is a Founding Director and Board Member of Feather in Her Cap, recognizing outstanding women in Animal Health.
Julia received her Bachelor of Arts from Indiana University in Bloomington, Indiana, with additional education at the Wharton School of Business, Columbia University, the University of Chicago, and Harvard University.
Paul Dick
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
